Piché ME, Tchernof A, Després JP (2020) Obesity phenotypes, diabetes, and cardiovascular diseases. Circ Res 126(11):1477–1500. https://doi.org/10.1161/CIRCRESAHA.120.316101

Article  PubMed  CAS  Google Scholar 

Heianza Y, Qi L (2017) Gene-diet interaction and precision nutrition in obesity. Int J Mol Sci 18(4):787

Article  PubMed Central  Google Scholar 

Williams MS, McKinney SJ, Cheskin LJ (2024) Social and structural determinants of health and social injustices contributing to obesity disparities. Curr Obes Rep. 13:617

Article  PubMed Central  Google Scholar 

NCD Risk Factor Collaboration (NCD-RisC) (2024) Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet 403(10431):1027–1050

De Lorenzo A, Gratteri S, Gualtieri P, Cammarano A, Bertucci P, Di Renzo L (2019) Why primary obesity is a disease? J Transl Med 17(1):169

Article  PubMed Central  Google Scholar 

Kemp JVA, Kumar V, Saleem A, Hashman G, Hussain M, Taylor VH (2023) Examining associations between women’s mental health and obesity. Psychiatr Clin North Am 46(3):539–549

Article  PubMed  Google Scholar 

Gasmi A, Mujawdiya PK, Nehaoua A, Shanaida M, Semenova Y, Piscopo S et al (2023) Pharmacological treatments and natural biocompounds in weight management. Pharmaceuticals (Basel). 16(2):212

Article  PubMed  PubMed Central  CAS  Google Scholar 

Mehta M, Istfan NW, Apovian CM (2021) Obesity: overview of weight management. Endocr Pract 27(6):626–635

Article  PubMed  Google Scholar 

Rasheed M (2023) Promoting nutritional education in primary school children. Br J Nurs 32(8):S14–S18

Article  PubMed  Google Scholar 

Lexchin J, Mintzes B (2023) Semaglutide: a new drug for the treatment of obesity. Drug Ther Bull 61(12):182–188

Article  PubMed  Google Scholar 

Levin PA, Nguyen H, Wittbrodt ET, Kim SC (2017) Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research. Diabetes Metab Syndr Obes 10:123–139

Article  PubMed  PubMed Central  CAS  Google Scholar 

Aroda VR, Erhan U, Jelnes P, Meier JJ, Abildlund MT, Pratley R et al (2023) Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes. Diabetes Obes Metab 25(5):1385–1397

Article  PubMed  CAS  Google Scholar 

Gallwitz B, Giorgino F (2021) Clinical perspectives on the use of subcutaneous and oral formulations of semaglutide. Front Endocrinol (Lausanne) 12:645507

Article  PubMed  Google Scholar 

Knudsen LB, Lau J (2019) The discovery and development of liraglutide and semaglutide. Front Endocrinol (Lausanne) 10:155

Article  PubMed  Google Scholar 

Xie Z, Yang S, Deng W, Li J, Chen J (2022) Efficacy and safety of liraglutide and semaglutide on weight loss in people with obesity or overweight: a systematic review. Clin Epidemiol 14:1463–1476

Article  PubMed  PubMed Central  Google Scholar 

Fornes A, Huff J, Pritchard RI, Godfrey M (2022) Once-weekly semaglutide for weight management: a clinical review. J Pharm Technol 38(4):239–246

Article  PubMed  PubMed Central  Google Scholar 

Sandhu H, Xu W, Olivieri AV, Lübker C, Smith I, Antavalis V (2023) Once-weekly subcutaneous semaglutide 2.4 mg injection is cost-effective for weight management in the United Kingdom. Adv Ther 40(3):1282–91

Article  PubMed  PubMed Central  CAS  Google Scholar 

Saumoy M, Gandhi D, Buller S, Patel S, Schneider Y, Cote G et al (2023) Cost-effectiveness of endoscopic, surgical and pharmacological obesity therapies: a microsimulation and threshold analyses. Gut 72(12):2250–2259

Article  PubMed  Google Scholar 

Kheirvari M, DadkhahNikroo N, Jaafarinejad H, Farsimadan M, Eshghjoo S, Hosseini S et al (2020) The advantages and disadvantages of sleeve gastrectomy; clinical laboratory to bedside review. Heliyon 6(2):e03496

Article  PubMed  PubMed Central  Google Scholar 

Barrichello S, Hourneaux de Moura DT, Hourneaux de Moura EG, Jirapinyo P, Hoff AC, Fittipaldi-Fernandez RJ et al (2019) Endoscopic sleeve gastroplasty in the management of overweight and obesity: an international multicenter study. Gastrointest Endosc 90(5):770–80

Article  PubMed  Google Scholar 

Collins M, Mason H, O’Flaherty M, Guzman-Castillo M, Critchley J, Capewell S (2014) An economic evaluation of salt reduction policies to reduce coronary heart disease in England: a policy modeling study. Value Health 17(5):517–524

Article  PubMed  Google Scholar 

Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D et al (2013) Consolidated health economic evaluation reporting standards (CHEERS)—explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value Health 16(2):231–50

Article  PubMed  Google Scholar 

Moher D, Liberati A, Tetzlaff J, Altman DG, medicine PGJP (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 6(7):e1000097

Google Scholar 

Kim N, Wang J, Burudpakdee C, Song Y, Ramasamy A, Xie YW et al (2022) Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States. J Manag Care Specialty Pharm 28(7):740–52

Article  Google Scholar 

Mital S, Nguyen HV (2023) Cost-effectiveness of antiobesity drugs for adolescents with severe obesity. JAMA Netw Open 6(10):e2336400

Article  PubMed  PubMed Central  Google Scholar 

Lee M, Lauren BN, Zhan T, Choi J, Klebanoff M, Abu Dayyeh B et al (2020) The cost-effectiveness of pharmacotherapy and lifestyle intervention in the treatment of obesity. Obes Sci Pract 6(2):162–170

Article  PubMed  Google Scholar 

Chubb B, Glah D, Capehorn M (2020) The cost-effectiveness of oral semaglutide in patients treated with currently available GLP-1 receptor agonists - a UK perspective. Value Health 23:S508-S

Article  Google Scholar 

Olivieri AV, Larsen S, Luckevich M, Chan K, Lamotte M (2022) The cost-effectiveness of subcutaneous semaglutide 2.4mg injection in the management of obesity in Canada using the core obesity model. Value Health 25(7):S426-S

Article  Google Scholar 

Iepsen EW, Zhang J, Thomsen HS, Hansen EL, Hollensted M, Madsbad S et al (2018) Patients with obesity caused by melanocortin-4 receptor mutations can be treated with a glucagon-like peptide-1 receptor agonist. Cell Metab 28(1):23-32.e3

Article  PubMed  CAS  Google Scholar 

Trenson L, Trenson S, van Nes F, Moyson C, Lannoo M, Deleus E et al (2022) Liraglutide for weight management in the real world: significant weight loss even if the maximal daily dose is not achieved. Obes Facts 15(1):83–89

Article  CAS  Google Scholar 

Li X, Morita S, Yamada H, Koga K, Ota W, Furuta T et al (2022) Free linoleic acid and oleic acid reduce fat digestion and absorption in vivo as potent pancreatic lipase inhibitors derived from sesame meal. Molecules 27(15):4910

Article  PubMed  PubMed Central  CAS  Google Scholar 

Alqahtani S, Qosa H, Primeaux B, Kaddoumi A (2015) Orlistat limits cholesterol intestinal absorption by Niemann-pick C1-like 1 (NPC1L1) inhibition. Eur J Pharmacol 762:263–269

Article  PubMed  CAS  Google Scholar 

Grudén S, Forslund A, Alderborn G, Söderhäll A, Hellström PM, Holmbäck U (2021) Safety of a novel weight loss combination product containing orlistat and acarbose. Clin Pharmacol Drug Dev 10(10):1242–1247

Article  PubMed  PubMed Central  Google Scholar 

Greenway FL, Shanahan W, Fain R, Ma T, Rubino D (2016) Safety and tolerability review of lorcaserin in clinical trials. Clin Obes 6(5):285–295

Article  PubMed  CAS  Google Scholar 

Wagner S, Brierley